DUBLIN (Reuters) - Irish drugmaker Elan Corp Plc said third-quarter revenue rose by 10 percent as sales of its multiple sclerosis (MS) drug grew. Tysabri sales, the blockbuster multiple sclerosis drug it co-markets with Biogen Idec, grew 3 percent to $403.8 million, while the number of patients rose 13 percent. Elan relies on Tysabri for the bulk of its earnings following the failure of bapineuzumab, one of the most anticipated experimental drugs for Alzheimer's disease being developed with Johnson & Johnson and Pfizer. Elan said third-quarter revenue rose to $306.6 million from $279. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment